Valuation AstraZeneca PLC Deutsche Boerse AG

Stocks

Market Closed - Deutsche Boerse AG 15:17:12 11/09/2026 BST			5-day change	1st Jan Change
137.40 ^EUR	+0.18%		-2.03%	-13.20%

09-11	AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal	MT
09-11	AstraZeneca's breast cancer pill fails in late-stage trial	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	182,034	209,442	209,268	203,171	287,813	245,576	-	-
Change	-	15.06%	-0.08%	-2.91%	41.66%	-14.68%	-	-
Enterprise Value (EV) ¹	206,417	232,365	231,778	227,741	311,187	265,026	257,343	248,828
Change	-	12.57%	-0.25%	-1.74%	36.64%	-14.83%	-2.9%	-3.31%
P/E	1,469x	64.1x	35.4x	29.1x	28.4x	20.3x	17.7x	15.3x
PBR	4.24x	5.65x	5.39x	5.02x	5.96x	4.55x	4.04x	3.44x
PEG	-	0x	0.4x	1.6x	0.6x	1.1x	1.2x	1x
Capitalization / Revenue	4.87x	4.72x	4.57x	3.76x	4.9x	3.88x	3.67x	3.44x
EV / Revenue	5.52x	5.24x	5.06x	4.21x	5.3x	4.19x	3.85x	3.49x
EV / EBITDA	27.2x	25.2x	17.1x	13.6x	16x	12x	10.6x	9.29x
EV / EBIT	20.8x	17.4x	15.9x	13.5x	16.8x	12.6x	11.1x	9.73x
EV / FCF	42.4x	26.7x	25.8x	22.9x	26.5x	28.1x	19.7x	16.9x
FCF Yield	2.36%	3.75%	3.88%	4.36%	3.78%	3.56%	5.08%	5.91%
Dividend per Share ²	2.87	2.9	2.9	3.1	3.2	3.339	3.561	3.66
Rate of return	2.44%	2.15%	2.15%	2.37%	1.72%	2.11%	2.25%	2.31%
EPS ²	0.08	2.11	3.81	4.5	6.54	7.782	8.932	10.32
Distribution rate	3,588%	137%	76.1%	68.9%	48.9%	42.9%	39.9%	35.5%
Net sales ¹	37,417	44,351	45,811	54,073	58,739	63,300	66,898	71,335
EBITDA ¹	7,586	9,237	13,580	16,691	19,476	22,158	24,298	26,772
EBIT ¹	9,928	13,350	14,534	16,928	18,478	21,072	23,269	25,560
Net income ¹	112	3,288	5,961	7,035	10,225	12,026	13,767	15,794
Net Debt ¹	24,383	22,923	22,510	24,570	23,374	19,450	11,766	3,252
Reference price ²	117.51	135.16	135.02	131.05	185.60	158.33	158.33	158.33
Nbr of stocks (in thousands)	1,549,159	1,549,528	1,549,926	1,550,317	1,550,726	1,551,024	-	-
Announcement Date	10/02/22	09/02/23	08/02/24	06/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	31.96x	11.62x	23.56x	0.62%	994B
JOHNSON & JOHNSON	29.63x	-	-	2.02%	640B
ABBVIE INC.	32.65x	7.56x	15.72x	2.69%	454B
ROCHE HOLDING AG	18.78x	4.58x	11.35x	2.9%	337B
NOVARTIS AG	19.52x	5.11x	12.66x	3.19%	261B
ASTRAZENECA PLC	20.44x	4.2x	12.01x	2.1%	246B
AMGEN INC.	24.19x	6.38x	11.35x	2.64%	204B
NOVO NORDISK A/S	12.74x	4.63x	9.67x	3.94%	190B
GILEAD SCIENCES, INC.	-43.8x	6.4x	24.98x	2.27%	178B
Average	16.23x	6.31x	15.16x	2.48%	389.42B
Weighted average by Cap.	23.28x	7.75x	17.19x	2.04%